Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) and Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Profitability
This table compares Collegium Pharmaceutical and Avenue Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Collegium Pharmaceutical | 5.93% | 91.43% | 15.57% |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
Earnings and Valuation
This table compares Collegium Pharmaceutical and Avenue Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Collegium Pharmaceutical | $808.21 million | 1.14 | $62.87 million | $1.24 | 22.77 |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | ($0.85) | -0.30 |
Collegium Pharmaceutical has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Collegium Pharmaceutical and Avenue Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Collegium Pharmaceutical | 0 | 3 | 3 | 1 | 2.71 |
| Avenue Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Collegium Pharmaceutical presently has a consensus target price of $52.60, indicating a potential upside of 86.33%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Avenue Therapeutics.
Insider and Institutional Ownership
17.3% of Avenue Therapeutics shares are held by institutional investors. 1.8% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Collegium Pharmaceutical beats Avenue Therapeutics on 12 of the 14 factors compared between the two stocks.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
